期刊文献+

急性冠脉综合征患者血浆chemerin和C反应蛋白水平升高 被引量:10

The elevated levels of plasma chemerin and C-reactive protein in patients with acute coronary syndrome
下载PDF
导出
摘要 目的探讨急性冠脉综合征患者血浆趋化素(chemerin)和C反应蛋白(CRP)水平变化。方法用ELISA测定急性心肌梗死(AMI)组、不稳定型心绞痛(UA)组、稳定型心绞痛(SA)组及对照组血浆chemerin水平,免疫发光夹心法测定CRP水平。结果 AMI组和UA组血浆chemerin水平显著高于对照组和SA组,且AMI组血浆chemerin水平显著高于UA组。AMI组和UA组血浆CRP水平显著高于对照组和SA组。血浆chemerin水平与CRP、空腹血糖、左室舒张末期内径显著正相关,与左室射血分数显著负相关。结论急性冠脉综合征患者血浆chemerin和CRP水平升高。 Objective To investigate the plasma levels of chemerin and C-reactive protein (CRP) in the patients with acute coronary syndrome. Methods The plasma levels of chemerin and CRP were respectively measured by ELISA and immune luminescence sandwich assay in 40 patients with acute myocardial infarction (AMI), 40 patients with unstable angina ( UA), 40 patients with stable angina (SA) and 40 control patients. Results The levels of chemerin and CRP were significantly higher in the AMI and UA groups than in the SA and control groups, and the level of chemerin was significantly higher in the AMI group than in the UA group. The level of chemerin was positively correlated with the level of CRP, fasting glucose and left ventricular end-diastolic diameter, but negatively correlated with left ventdcular ejection fraction. Conclusion The plasma levels of chemedn and CRP are elevated in patients with acute coronary syndrome.
出处 《细胞与分子免疫学杂志》 CAS CSCD 北大核心 2015年第7期953-956,共4页 Chinese Journal of Cellular and Molecular Immunology
基金 国家自然科学基金(81070237)
关键词 急性冠脉综合征 CHEMERIN C反应蛋白 炎症 acute coronary syndrome chemerin C-reactive protein inflammation
  • 相关文献

参考文献7

二级参考文献77

  • 1DU X Y, ZABEL B A, MYLES T, et al. Regulation of chemerin bioactivity by plasma carboxypeptidase N, carboxypeptidase B (activated thrombin-activable fibrinolysis inhibitor), and platelets[J]. J Biol Chem, 2009,284:751--758.
  • 2WITTAMER V, BONDUE B, GUILLABERT A, et al. Neutrophil-mediated maturation of chemerin., a link between innate and adaptive immunity[J]. J Immunol, 2005,175 :487 - 493.
  • 3GUAI.ILLO O, GONZALEZ-JUANATEY J R, LAGO F. The emerging role of adipokines as mediators of cardiovascular function: physiologic and clinical perspeetives[J].Trends Cardiovasc Med, 2007, 17:275--283.
  • 4LEHRKE M, BECKER A, GREIF M, et al. Chemerin is associated with markers of inflammation and components of the metabolic syndrome but does not predict coronary atheroselerosis[J]. Eur J Endocrinol,2009,161: 339 - 344.
  • 5SPIROGLOU S G, KOSTOPOULOS C G, VARA- KIS J N, et al. Adipokines in periaortic and epicardial adipose tissue: differential expression and relation to atherosclerosis[J].J Atheroscler Thromb, 2010,17: 115--130.
  • 6GORALSKI K B, SINAL C J. Elucidation of chemer in and ehemokine-like receptor-1 function in adipo- cytes by adenoviral mediated shRNA knockdown of gene expression[J].Methods Enzymol, 2009,460 : 289 --312.
  • 7BOZAOGLU K, BOLTON K, MCMILLAN J, et al. Chemerin is a novel adipokine associated with obesity and metabolic syndrome [J].Endocrinology, 2007, 148..4687-4694.
  • 8ERNST M C, SINAI. C J. Chemerin: at the cross roads of inflammation and obesity[J]. Trends Endocrinol Metab,2010,21 ..660-667.
  • 9WANG Z, NAKAYAMA T. Inflammation, a link between obesity and cardiovascular disease[J]. Mediators Inflamm, 2010,53 : 5 - 18.
  • 10BOZAOGLU K, SEGAL D, SHIELDS K A, et al. Chemerin is associated with metabolic syndrome phenotypes in a Mexican-American population[J]. J Clin Endocrinol Metab, 2009,94 : 3085- 3088.

共引文献94

同被引文献97

  • 1佟凤芝,马荣,陈莹洁.早发急性冠脉综合征患者血脂与血尿酸指标分析[J].医学信息(医学与计算机应用),2014,0(33):37-37. 被引量:1
  • 2鞠延玲,鲍百丽.冠心病患者T淋巴细胞亚群、同型半胱氨酸与疾病的相关性[J].中国老年学杂志,2014,34(9):2432-2433. 被引量:11
  • 3赵小祺,王晓玲,焦宏,马建伟,陈立峰,王春光.四逆汤与福辛普利预处理对急性心肌梗死大鼠氧化应激的影响[J].中国老年学杂志,2014,34(5):1323-1325. 被引量:8
  • 4中风病诊断与疗效评定标准(试行)[J].北京中医药大学学报,1996,19(1):55-56. 被引量:5879
  • 5Piper A, Song Y, Eves N D, et al. Year in review 2013 : Acute lung injury, interstitial lung diseases, sleep and physiology [ J ]. Respirology, 2014, 19(3) : 428 -437.
  • 6Sweeney R M, Griffiths M, Mcauley D. Treatment of acute lung injury: Current and emerging pharmacological therapies [ J ]. Semin Respir Crit Care Med, 2013, 34(4) : 487 -498.
  • 7Costa E L, Amato M B. The new definition for acute lung injury and acute respiratory distress syndrome: is there room for improvement ? [J]. Curr Opin Crit Care, 2013, 19(1) : 16 -23.
  • 8Liu K D, Wilson J G, Zhuo H, et al. Design and implementation of the START(STem cells for ARDS treatment) trial, a phase 1/2 trial of human mesenchymal stem/stromal ceils for the treatment of moderate-severe acute respiratory distress syndrome [ J/OL ]. Ann Intensive Care, 2014, 4: 22. doi: 10. 1186/s13613 -014 -0022 -z. eCollection 2014.
  • 9Sehmickl C N, Biehl M, Wilson G A, et al. Comparison of hospital mortality and long-term survival in patients with acute lung injury/ ARDS vs cardiogenic pulmonary edema[ J ]. Chest, 2015, 147 ( 3 ) : 618 -625.
  • 10Ruhl A P, Lord R K, Panek J A, et al. Health care resource use and costs of two-year survivors of acute lung injury: An observational cohort study[J]. Ann Am Thorae Soc, 2015, 12(3) : 392 -401.

引证文献10

二级引证文献59

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部